Revamping a 50-Year-Old Technology: How Precision Workflows Are Revolutionizing Monoclonal Antibody Discovery

Creative Biolabs launches a series of monoclonal development solutions with improved precision and ultra-high throughput.

Fifty years after the birth of hybridoma technology—a game-changer in monoclonal antibody development—scientists are still trying to rev up this “classic engine“. A 2025 paper published in Nature Communications sheds light on hybridoma methods. Moreover, showcasing how targeted selection of antibody-secreting cells (ASCs) and optimized electrofusion techniques can drastically boost fusion efficiency and yield highly functional hybridomas. Thus, a back-to-the-future moment for hybridoma tech, turbocharged with next-gen tools. Creative Biolabs has long championed hybridoma technology.

Aiming to revamp this old guard with its modernized approach that blends traditional rigor with breakthrough enhancements, incorporating custom immunization, cell fusion, clone screening, subcloning, and isotyping. Additionally, integrated with AI-driven sequence analysis to fine-tune clone selection.

The future belongs to platforms that can adapt. We are building a hybridoma platform that is not just about cranking out antibodies, but precision, scalability, and real-world application, said a scientist at Creative Biolabs.

The Power of Choice: From Libraries to Clinics

Creative Biolabs offers premade library-based binder discovery solutions, one that takes less time than hybridoma. And enables clients to rapidly screen binders against hard-to-hit targets using human, mouse, camelid, or synthetic libraries. Specifically for those projects requiring human-origin antibodies. Creative Biolabs established a proprietary platform to provide an all-human antibody repertoire for HuScL-6, HuFabL-5, etc.

In addition to these premade libraries for discovering peptide and antibody drugs, we can perform various premade library screening strategies for different target types. Such as peptides, proteins, and cells. The scientist introduces “targeting precise epitopes,” such as receptor and ligand binding epitopes, TCR-like epitopes, and idiotypic epitopes.

Additionally,

  • Solid-Phase Screening
  • Solution-Sorting Screening
  • Cell-based Screening
  • In Vivo Screening
  • Ex Vivo Screening

To round out its mAb discovery pipeline, Creative Biolabs also offers comprehensive antibody property analysis. Covering thermal stability, aggregation tendency, binding kinetics, and more, which comprises a full-service suite designed to de-risk candidates before they enter clinical territory. Core technologies are surface plasmon resonance (SPR), bio-layer interferometry (BLI), isothermal titration calorimetry (ITC), and microscale thermophoresis (MST).

Fueling Tomorrow’s Innovators

Creative Biolabs also invests in future talent in addition to fueling scientific discovery, with their 2025 scholarship program now in full swing. Aims to offer financial support and career mentorship to undergraduate and graduate students in life sciences around the world.

This scholarship is more than funding, but a way we recognize potential, the scientist says.

Learn more: https://www.creative-biolabs.com/

About

Creative Biolabs has the belief that discovering therapeutic antibodies with exceptional specificity and bioavailability is a cornerstone of modern drug development. Further, it not only supports biotechnology innovations in related fields but also encourages the next generation of scientific trailblazers.

Additionally, to stay updated with the latest developments in STEM research, visit ENTECH Online. Basically, this is our digital magazine for science, technology, engineering, and mathematics. Furthermore, at ENTECH Online, you’ll find a wealth of information.

Leave Your Comment

Warning